SecBot SecBot
ANALYST-DOWNGRADE

REGN

REGENERON PHARMACEUTICALS, INC.
BEARISH
Impact 2/10
Horizonmonths Processed6mo ago SECanalyst-REGN-citigrou-20260518
2 firms acted on REGN: Citigroup, Leerink Partners
Actionable Insight ▼ Bearish

The downgrades from low-accuracy firms, while cautionary, are not statistically strong. Given consensus bullishness and improving EPS revisions, traders could view weakness toward $700 as a potential buying entry, but should wait for price stability or confirmation from a high-accuracy firm before committing.

DirectionBearish
Confidencemedium
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$629.34
T+0 close · May 18, 2026 · via day close
Latest settled
+26.80%
T+60 · $797.99
Vs SPY
+22.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $629.34entry
  2. T+1 · 6mo ago +0.07%α +0.72% · $629.76
  3. T+5 · 6mo ago +0.45%α −1.17% · $632.17
  4. T+20 · 5mo ago −2.28%α −4.47% · $614.98
  5. T+60 · 3mo ago +26.80%α +22.22% · $797.99
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

On May 18, 2026, two firms downgraded Regeneron Pharmaceuticals (REGN). Citigroup cut from Buy to Neutral, slashed price target from $900 to $700, nearly in line with the current $698.25. Leerink Partners downgraded from Outperform to Market Perform with a $641 target, implying ~8% downside. Both firms have below-average track records on REGN (Citi 43% accuracy on 7 calls, Leerink 50% on 2 calls). Consensus remains strongly bullish: 30 of 38 analysts (79%) rate Buy or Strong Buy, with a mean price target of $875.31 (25.4% upside). EPS revision momentum is positive, with 15 upgrades vs 6 downgrades for the next quarter. Insider sales are small and routine; institutional activity is mixed (Two Sigma trimming but Norges Bank adding a $1B position). While the cluster downgrade signals near-term caution, the positive consensus and earnings momentum suggest the stock may find support near $700. The low accuracy of the downgrading firms reduces the significance of this action.

Impact Score

Base Score
2/7
LLM Adjustment
+0
Final Score
2/10

Consensus & Targets

Buy / Strong Buy
30 (79%)
Hold
8
Sell / Strong Sell
0
Total Analysts
28
Mean PT
$875.31
Median PT
$882.50
High PT
$1,057.00
Low PT
$730.00
Current Price
$698.25
Implied Upside
+25.4%

Consensus is heavily bullish: 30 of 38 analysts (79%) rate Buy or Strong Buy, 8 Hold (21%), and 0 Sell. The average price target is $875.31 with a median of $882.5. The downgrades are contrarian to the consensus view, which sees 25.4% upside from current levels.

Mean price target $875.31, median $882.5, high $1057, low $730. Current price $698.25 implies 25.4% upside to mean. Citigroup's new $700 PT of $700 is below the consensus low of $730, and Leerink's $641 is even lower. Both new targets are well below the consensus mean of $875.31, reflecting a more pessimistic view than the average analyst.

Recent Analyst Activity

DateFirmActionRatingPrice Target
2026-05-18JP MorganmaintainOverweight$850.00
2026-05-18Piper SandlermaintainOverweight$855.00
2026-05-18Wells FargomaintainEqual-Weight$700.00
2026-05-18RBC CapitalmaintainSector Perform$707.00
2026-05-18CitigroupdowngradeNeutral$700.00
2026-05-18Leerink PartnersdowngradeMarket Perform$641.00
2026-05-01GuggenheimmaintainBuy$995.00
2026-04-30RBC CapitalmaintainSector Perform$762.00
2026-04-30BarclaysmaintainOverweight$917.00
2026-04-30Truist SecuritiesmaintainBuy$796.00

In the last 30 days, REGN has seen 0 upgrades and 2 downgrades (these). EPS revisions for the current quarter are positive: 15 upward vs 6 downward in 30 days, with consensus rising $12.30 to $13.09. Full-year EPS also revised up 16 vs 7 down. This positive earnings momentum contrasts with the negative analyst action.

Firm Track Record: Citigroup

Citigroup accuracy: 55% on 4355 calls | avg return: 4.9%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

FirmAccuracyCallsAvg Returnvs Average
UBS67%4/65.1%top tier
Canaccord Genuity57%4/79.4%above average
TD Cowen50%1/23.1%below average
Bernstein50%1/26.2%below average
Cantor Fitzgerald50%4/8-4.5%below average
BMO Capital50%3/6-3.7%below average
Morgan Stanley50%5/104.1%below average
Goldman Sachs50%1/2-3.6%below average
Leerink Partners50%1/2-23.7%below average
Evercore ISI Group50%1/2-4.9%below average

Citigroup has a 43% accuracy rate on 7 REGN calls, with an average return of 3.8%, below the average. Leerink is 50% on 2 calls with a -23.7% average return, the worst among all firms. The best performer is UBS (67% accuracy on 6 calls, +5.1% return); the worst by accuracy is RBC Capital (33% on 18 calls, -8.9%). Both downgrading firms are among the lowest in accuracy on this name.

Earnings Estimates

Next earnings: Jul 30, 2026

PeriodEPS Est.EPS RangeRevenueRevisions (7d)
0q$10.86$8.27 to $13.25$3.8B↑2 ↓0
+1y$48.20$41.10 to $60.05$17.6B↑2 ↓0
+1q$13.09$9.36 to $17.10$4.2B↑5 ↓0
0y$46.50$38.82 to $53.61$15.9B↑6 ↓0

Cross-Platform Signals

Insider Trades (90d)
0 buys / 4 sells
Congressional
Ro Khanna (democrat): buy $1,001 - $15,000
Institutional
TWO SIGMA INVESTMENTS, LP: trim (-40.2%)
Institutional
RENAISSANCE TECHNOLOGIES LLC: near_exit (-96.7%)
Institutional
SOUND SHORE MANAGEMENT INC /CT/: add (52.9%)

Insider sales are small ($10k by CFO Ryan in April/May, $38k by director Zoghbi in February) and likely routine; no informative cluster. Congressional: Rep. Khanna bought $1k‑$15k in April, negligible. Institutional actions are mixed: Two Sigma trimmed 40% and Renaissance near-exited (‑97%), but Norges Bank initiated a $1B market position and Sound Shore added 53%. Short interest is not available. Overall, the downgrade divergence with still‑positive institutional buying and upward EPS revisions, reducing the joint signal reliability of the bearish signal.

Investment Themes

Documents Analyzed

Report based on filing metadata.

Track record

53 reports on REGN

Performance horizon

10 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (11h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026